City Pharma Profits up 40% in 4QFY25
Citi Pharma Limited (CPHL) has posted a profit of Rs 213 million during the 4QFY25 which is up 40 % compared to the same period last year.
The company announced 4QFY25 results on Thursday, where in company posted earnings of Rs213mn (EPS Rs0.93) as compared to net earnings of Rs152mn (EPS Rs0.67) during the same period last year, up by 40%YoY. Health Body Calls for appointments at PIMS
The earnings growth is primarily attributable to expansion in gross margins. The company also announced a final cash dividend of Rs 3.5/share for FY25.
During 4QFY25, the company’s topline posted growth of 6%YoY to Rs3bn, primarily due to a rebound in the pharma volumetric sales supported by Formulation sales to the government hospital.
The company’s gross margin stood at 18% in 4QFY25 versus 8% in the same period last year. We believe this improvement is likely driven by a higher contribution from formulations in the revenue mix, which typically carry higher margins than APIs,” Sherman Research said.
Finance cost clocked in at Rs98mn (down 1%YoY) during 4QFY25 amid lower interest rates during the period.
In 4QFY25, the company posted effective taxation of 35% as compared to 7% during the same period last year.
During FY25, The company posted EPS of Rs3.9 ( up7%YoY) compared to EPS of Rs3.6 in the same period last year, primarily due to slight growth in the Revenue Rs13bn ( up 6%YoY) due to weak international API prices.
